Estradiol + Progesterone: Your HRT Explained

The same dose not affect every woman the same way.

The dose printed on your prescription tells you how much medication you're receiving. It doesn't tell you exactly how much estradiol will be circulating in your blood.

Two women using the same estradiol patch can have different blood estradiol levels because of differences in absorption, metabolism, body chemistry, timing of the blood test and even where the patch is applied.

That's one reason your doctor may adjust your dose based on how you feel rather than trying to make your blood level match another woman's.

The amount of progestogen needed to protect the uterine lining isn't determined by the progesterone number alone. It is considered in relation to the estrogen dose, the type of estrogen, the progestogen being used, and the schedule.

For women taking systemic estrogen who have a uterus, progesterone is prescribed to protect the uterine lining. 100 mg of oral micronized progesterone daily is one commonly used continuous regimen.

Another commonly used approach is 200 mg daily for part of each month (often called cyclic or sequential therapy).

Women may be prescribed higher continuous doses (200 mg or 300 mg) of oral micronized progesterone to better manage severe menopausal symptoms like insomnia, night sweats, or anxiety, or to address higher systemic absorption needs and individual metabolic differences.

Some doctors may increase the dose of micronized progesterone when the dose of estradiol is high or if unscheduled spotting/bleeding occurs.

The appropriate regimen depends on the estrogen dose, whether progesterone is taken continuously or cyclically, how long it is taken each month, the route of administration, and your tolerance for it another individual circumstances.

Your doctor prescribed both because they treat different types of menopausal symptoms.

The estradiol gel is systemic therapy applied to the skin to treat body-wide symptoms like hot flashes and night sweats, while the vaginal cream is a low-dose local treatment applied directly to relieve vaginal dryness, irritation, or urinary issues. Systemic doses often do not fully resolve local vaginal changes.

Why You Need Both Forms

Estradiol Gel (Systemic):

• Absorbed through the skin into your bloodstream.
• Treats whole-body symptoms such as hot flashes, night sweats, and sleep disruptions.

Vaginal Estradiol Cream (Local):

• Stays mostly local to the vaginal and urinary tissues with minimal absorption into the rest of the body.
• Treats local discomfort like vaginal dryness, burning, painful intercourse, or frequent urinary tract infections.
• Safe to use alongside systemic gel because the vaginal dose is very low and does not significantly add to your overall body hormone levels.
  

Not necessarily.

Your clinician may consider increasing your estrogen dose if symptoms aren't adequately controlled, but persistent symptoms don't automatically mean you need more estrogen.

Reasons Why Hot Flashes Persist

• Low Dose: Your current dosage may be too low to control your symptoms.
• Poor Absorption: The patch may not stick well or might be placed in an area with too much movement or oil.
• Timing: It can take up to 2 to 3 months for transdermal estrogen levels to fully stabilize for maximize relief.

If you're still having significant symptoms after you've been using your HRT consistently for a reasonable period of time, talk with your healthcare provider.

They can determine whether the route of administration is right for you, whether you're absorbing the medication as expected, whether another medical issue could be contributing to your symptoms, or whether a different treatment approach would work better for you.

The dose printed on your prescription tells you how much medication you're receiving. It doesn't tell you exactly how much estradiol will be circulating in your blood.

Two women using the same estradiol patch can have different blood estradiol levels because of differences in absorption, metabolism, body chemistry, timing of the blood test and even where the patch is applied.

That's one reason your doctor may adjust your dose based on how you feel rather than trying to make your blood level match another woman's.

Certain signs suggest that the current dose may be too low.

If hot flashes, night sweats, mood swings, fatigue, or vaginal dryness remain persistent after several months of treatment, an increase in dosage may be required.

Additionally, if symptoms improve initially but return over time, this could indicate that the body is not receiving enough hormones.

Everyone’s body and needs are different, but most people typically see results within 1–2 months. Talk with your doctor before making any adjustments to your dosage or schedule.

If your estrogen dose is too high, you may experience physical side effects.

Common Signs of Excess Estrogen

• Noticeable breast swelling, pain, or heavy sensitivity.
• Digestive and fluid changes:
• Persistent abdominal bloating, puffiness, or swelling in the hands and feet.
• Frequent headaches or migraines.
• Bleeding changes: Unexplained spotting or heavy breakthrough bleeding if you still have a uterus.
• Mood fluctuations: Sudden irritability, anxiety, or emotional volatility.

These symptoms don't prove that your estrogen dose is too high. They can have other causes, and some are temporary when starting or changing HRT.

Always consult your doctor before making any changes to your medication.

Sometimes—but there isn't one blood level that every woman on HRT needs to reach.

For most women, clinicians adjust systemic estrogen based primarily on symptom relief, side effects, treatment goals, age, time since menopause, and individual risk factors rather than trying to bring a blood estradiol level into a specific target range.

That's why you may hear your doctor say, “We treat the symptoms, not the number.”

But that doesn't mean serum estradiol levels are biologically meaningless.

Is there an optimal estradiol level?

Research suggests that the amount of estradiol circulating in your blood can matter for some of the benefits of estrogen therapy, particularly its effects on bone and the cardiovascular system.

Recent research examining transdermal estradiol found that serum levels around 60 pg/mL were consistent with the estradiol exposure associated with favorable skeletal and cardiovascular findings in earlier studies. Other clinical guidance has suggested ranges such as 40–100 pg/mL when serum testing is used to help guide treatment in certain circumstances.

However, these numbers are not an established universal target for every woman taking HRT.

The relationship between blood estradiol and treatment benefit is complicated by the type of estrogen, route of administration, timing of the blood draw, laboratory assay, individual metabolism and the reason the hormone is being prescribed.

For example, a woman using a transdermal patch may have a different blood level than another woman using the same patch, even though both are receiving the same prescribed dose.

So why don't doctors routinely check it?

Because for most women, there is not enough evidence to say that adjusting HRT until a particular serum estradiol number is reached produces better outcomes than adjusting treatment according to symptoms and clinical response.

Major menopause guidelines therefore do not recommend routine serum estradiol testing for most women using HRT.

There are situations where testing can be useful—for example, when symptoms aren't responding as expected, absorption is in question, a woman is using a formulation where dosing is difficult to assess, or there is uncertainty about whether she is receiving too much or too little estrogen.

The bottom line:

Your estradiol level is not a number you necessarily need to “hit.” But it is also not a meaningless number.

For most women, symptoms and clinical response remain the starting point for adjusting HRT. Serum estradiol testing can provide additional information when there is a specific reason to measure it.

And if you have a specific treatment goal—such as protecting bone health—it's reasonable to ask your healthcare provider how they are determining that your estrogen dose is adequate for that goal.

Yes, it's possible.

Women can absorb very different amounts of estradiol from the same patch or gel dose. In a study of more than 1,500 women using transdermal estradiol, blood levels varied substantially even among women using the same dose. About 1 in 4 women using the highest licensed dose had estradiol levels below 200 pmol/L (about 55 pg/mL).

Could my patch or gel not be absorbing properly?

• The type of product: The study found more variation among gel users than patch users.
• Age: Women age 50 and older were more likely to have lower estradiol levels.
• Skin: Skin thickness, hydration, blood flow and other characteristics can affect absorption.
• Application: Where and how you apply the product matters. For gel, the amount of skin covered can also affect absorption.
• Washing after applying gel: Washing the skin within an hour of application reduced average estradiol levels in one study by as much as 22%.
• Patch adhesion: If a patch isn't adhering properly, absorption can be reduced.

So if you're using your HRT correctly but your symptoms aren't improving as expected, the problem may not be that you need more estrogen. You may not be absorbing as much as expected.

Your healthcare provider may consider whether your application technique is correct, whether you've had enough time to respond, whether a different dose or delivery method makes sense, and—in some situations—whether checking your serum estradiol level would be useful.

Bottom Line:

The same dose does not necessarily produce the same estradiol level in every woman.

There isn't a single waiting period that applies to every woman.

But if you're still having significant symptoms after you've been using your HRT consistently for a reasonable period of time, don't assume you simply need to keep waiting—or that HRT isn't working for you.

Your healthcare provider can look at several possibilities:

• Is the dose too low?
• Are you absorbing the medication adequately?
• Would a different delivery method work better?
• Is something else causing the symptom?

A study of more than 1,500 women using transdermal estradiol found that serum estradiol levels vary considerably between women using the same transdermal dose. It also found that a blood test can be useful when a woman's response is suboptimal, particularly when she's already using a higher licensed dose.

That means persistent symptoms can sometimes be a reason to investigate what's happening rather than simply increasing the dose and hoping for the best.

If your symptoms aren't improving, or you're having troublesome side effects, talk with your healthcare provider rather than adjusting your dose on your own.

Bleeding or spotting is common when you first start HRT, particularly during the first few months.

Your uterus is responding to changes in estrogen and progestogen, and it can take time for the endometrial lining to settle into a new pattern.

With continuous combined HRT—estrogen and progestogen taken every day—irregular spotting or bleeding is common during the first 4–6 months.

If you're using sequential or cyclic HRT, bleeding at the end of the progestogen portion of your cycle is expected. This is called withdrawal bleeding.

So the first question to ask isn't simply:

“Why am I bleeding?”

It's:

“What kind of HRT am I taking, and when is bleeding expected with this regimen?”

Check in with your healthcare provider if unexpected bleeding occurs.

This is an important one because women can be given very different instructions depending on whether they are taking continuous or sequential HRT.

Continuous combined HRT

You take estrogen and progestogen continuously, without a monthly break.

The goal is eventually to have no bleeding, although spotting and irregular bleeding are common during the first several months.

Sequential/cyclic HRT

You take estrogen continuously but take your progestogen for part of each month.

A predictable withdrawal bleed toward the end of the progestogen phase is expected.

If you're unsure which type you're taking, ask your healthcare provider or pharmacist. Knowing your regimen makes your bleeding pattern much easier to understand.

There isn't a single rule for every woman, but irregular bleeding is common during the first six months after starting HRT.

The BMS guideline also allows for a period of adjusting the HRT regimen when bleeding occurs within the first six months of starting treatment, or within three months after changing the HRT dose or preparation, in women without significant endometrial cancer risk factors.

That doesn't mean you should ignore bleeding for six months.

If the bleeding is heavy, prolonged, or concerning to you, contact your healthcare provider sooner.

And if bleeding continues beyond the expected settling-in period, it should be evaluated.

Don't automatically assume it's just HRT.

If you have been taking HRT consistently and have been free of bleeding, then start bleeding again, it's worth talking with your healthcare provider.

The BMS guideline recommends prompt evaluation when bleeding first occurs more than six months after starting HRT or more than three months after changing the HRT preparation.

Bleeding can have many causes, including changes in your HRT regimen, missed doses, vaginal or cervical problems, polyps or fibroids. Less commonly, it can be a sign of endometrial cancer.

Most bleeding does not mean cancer—but unexplained bleeding should be checked.

Not necessarily.

Bleeding can happen for many reasons, and you shouldn't assume that your progesterone dose is too low.

However, progesterone plays an important role in controlling the growth of the uterine lining when you're taking systemic estrogen.

Your healthcare provider may review:

• your estrogen dose
• your progesterone dose
• how often you're taking progesterone
• whether you've missed any doses
• the type and route of progesterone
• how long you've been on your current regimen

Sometimes changing the progestogen or HRT preparation can improve unscheduled bleeding.

Contact your healthcare provider if:

• Bleeding is heavy or prolonged
• Bleeding continues or becomes worse after the initial settling-in period
• You start bleeding after you have been free of bleeding for a while
• You first develop bleeding more than six months after starting HRT
• You develop bleeding more than three months after changing your HRT
• You're worried about the bleeding for any reason

The BMS guideline recommends urgent transvaginal ultrasound in some of these situations, particularly when bleeding is heavy/prolonged or begins outside the expected adjustment periods.

Your evaluation may include a discussion of:

Your HRT regimen

Your clinician will want to know exactly what estrogen and progestogen you're taking, the doses, how often you take them, and whether you've missed any doses.

A pelvic examination

This may help identify causes of bleeding originating from the vagina, cervix or vulva.

A transvaginal ultrasound

This uses an ultrasound probe placed in the vagina to look at the uterus and measure the thickness and appearance of the endometrial lining.

Endometrial biopsy and/or hysteroscopy

If the ultrasound or your symptoms suggest that further investigation is needed, your clinician may recommend taking a sample of the uterine lining or looking inside the uterus with a small camera.

The BMS guideline uses different endometrial-thickness thresholds depending on whether a woman is using continuous combined or sequential HRT.

If you've had a total hysterectomy and no longer have a uterus, you generally don't need a progestogen to protect the uterine lining, so bleeding while taking estrogen should not simply be attributed to “normal HRT bleeding.”

If you have had a hysterectomy but still have a cervix, or if you had a partial hysterectomy, the situation can be different. Talk with your healthcare provider about what tissues remain and what could be causing bleeding.

If you're having bleeding on HRT, keep a simple record of:

• the date
• how heavy it is
• how many days it lasts
• whether it's spotting or a period-like flow
• when you take your progesterone
• any recent changes to your HRT

This can make it much easier for your clinician to see whether there's a pattern.

The BMS guideline specifically recommends reviewing the pattern of bleeding, HRT preparations and individual risk factors as part of the initial assessment.

Estrogen-only vs. combined HRT

If you have a uterus, estrogen is generally prescribed with a progestogen to protect the uterine lining.

Combined HRT (estrogen + progestogen) is associated with a small increase in breast cancer risk, particularly with longer use.

After five years of hormone replacement therapy (HRT), the risk of breast cancer depends heavily on the type of hormones used. Combined estrogen-progestogen HRT shows a small, measurable increase in risk after five years, adding about 3 to 5 extra cases per 1,000 women

Estrogen-only HRT, which is generally used by women who no longer have a uterus, has a different risk profile. In the WHI randomized trial, estrogen-only therapy did not increase breast cancer risk and was associated with a lower incidence of breast cancer during follow-up.

Yes. Breast cancer risk appears to increase with longer duration of combined HRT use, although the absolute increase in risk for an individual woman is small.

Age and timing also matter when considering the overall benefits and risks of HRT. For healthy women who start HRT before age 60 or within 10 years of menopause, the overall benefit-risk balance is generally favorable.

There isn't a universal five-year cutoff after which every woman should stop HRT. The decision should be reassessed periodically based on your symptoms, treatment goals, age and individual risk factors.

It may.

Research suggests that breast cancer risk may differ depending on the type of progestogen used with estrogen. Some observational studies have found a more favorable breast cancer risk profile with micronized progesterone than with certain synthetic progestins.

That doesn't mean micronized progesterone prevents breast cancer, and we don't yet have the same level of long-term randomized evidence for micronized progesterone that we have for some older HRT formulations.

But “progesterone” and “progestin” are not simply two names for the same medication, and the distinction may matter.

This is a very different situation.

For women with a personal history of breast cancer, particularly hormone-receptor-positive breast cancer, systemic HRT is generally avoided because estrogen can stimulate hormone-sensitive breast cancer cells.

If you're experiencing severe menopause symptoms after breast cancer treatment, talk with your oncologist or menopause specialist about nonhormonal options and whether any local treatment may be appropriate for you.

Possible Safe Alternatives and Exceptions

Vaginal Estrogen: Low-dose topical treatments (creams, rings, or tablets) for vaginal dryness stay mostly local and are generally considered safe for survivors after consulting an oncologist.

Non-Hormonal Medications: Prescription drugs like SSRIs/SNRIs (such as venlafaxine), gabapentin, or fezolinetant can manage hot flashes effectively without hormones.

Low-dose vaginal estrogen is different from systemic HRT.

It delivers a very small amount of estrogen directly to vaginal tissue, with much less systemic absorption than an estrogen patch, pill or gel. It is commonly used for vaginal dryness, painful sex and some urinary symptoms.

For women with a history of breast cancer, however, don't assume that vaginal estrogen is automatically appropriate just because it is low-dose. The decision should be individualized with your healthcare team, particularly for women taking aromatase inhibitors.

HRT isn't one treatment with one breast-cancer risk.

The risk depends on which hormones you're taking, whether you need a progestogen, how long you use them, when you start, and your individual risk factors.